InSite Vision to Report Third Quarter 2012 Financial Results on November 8, 2012.
Company management will host a conference call that day beginning at 4:30 p.m. ET/1:30 p.m. PT to discuss third quarter financial results and to review recent accomplishments and upcoming milestones. Investors will be invited to ask questions following management's prepared remarks.
Analysts and investors can participate in the conference call by dialing 888-679-8037 for domestic callers and 617-213-4849 for international callers using the pass code 68680828. A telephone replay will be available following the conclusion of the call by dialing 888-286-8010 for domestic callers and 617-801-6888 for international callers using the pass code 27814489.
The live conference call will also be webcast and available on the Investor Relations page of the company's website at www.insitevision.com. A press release detailing third quarter 2012 financial results will be posted to the company's website and furnished to the Securities and Exchange Commission on a Form 8-K.
About InSite Vision
InSite Vision is advancing new ophthalmic products for unmet eye care needs based on its innovative DuraSite([R]) and DuraSite 2[R] platform technologies. The DuraSite and DuraSite 2 drug delivery systems extend the duration of drug retention on the surface of the eye, thereby reducing frequency of treatment and improving the efficacy of topical drugs. DuraSite is currently leveraged in two commercial products for the treatment of bacterial eye infections, AzaSite([R]) (azithromycin ophthalmic solution) 1%, marketed in the U.S. by Merck, and Besivance([R]) (besifloxacin ophthalmic suspension) 0.6%, marketed by Bausch + Lomb. InSite Vision is also advancing three novel ophthalmic therapeutics through Phase 3 clinical studies: AzaSite Plus([TM]) and DexaSite([TM]) for the treatment of eye infections, and BromSite([TM]) for pain and swelling associated with ocular surgery. DuraSite 2 incorporates InSite's proprietary bioadhesive core technology with a cationic polymer to achieve sustained and enhanced ocular delivery of drugs. The DuraSite 2 platform will be applied to InSite's future pipeline product candidates and available through a broad licensing program for advanced ophthalmic drug development. For further information on InSite Vision, please visit www.insitevision.com.
AzaSite([R]) and DuraSite([R])are registered trademarks of InSite Vision Incorporated.
BESIVANCE([R]) is a registered trademark of Bausch + Lomb Incorporated.
|Printer friendly Cite/link Email Feedback|
|Article Type:||Financial report|
|Date:||Oct 26, 2012|
|Previous Article:||100th Anniversary of "Theater in a Suitcase" Invention Ushers in 2012 National Distance Learning Week.|
|Next Article:||Lancaster Pollard Leads All Lenders in Seniors Housing Lending Activity.|